UK GLOBAL HEALTHCARE LIMITED

Company Registration Number:
09800013 (England and Wales)

Unaudited abridged accounts for the year ended 31 March 2024

Period of accounts

Start date: 01 April 2023

End date: 31 March 2024

UK GLOBAL HEALTHCARE LIMITED

Contents of the Financial Statements

for the Period Ended 31 March 2024

Balance sheet
Notes

UK GLOBAL HEALTHCARE LIMITED

Balance sheet

As at 31 March 2024


Notes

2024

2023


£

£
Fixed assets
Investments: 3 2,923,977 2,923,977
Total fixed assets: 2,923,977 2,923,977
Current assets
Debtors:   14,864,052 14,913,048
Cash at bank and in hand: 147 1,066
Total current assets: 14,864,199 14,914,114
Creditors: amounts falling due within one year:   (16,454,781) (16,569,277)
Net current assets (liabilities): (1,590,582) (1,655,163)
Total assets less current liabilities: 1,333,395 1,268,814
Total net assets (liabilities): 1,333,395 1,268,814
Capital and reserves
Called up share capital: 61,330 61,330
Share premium account: 12,252,000 12,252,000
Profit and loss account: (10,979,935) (11,044,516)
Shareholders funds: 1,333,395 1,268,814

The notes form part of these financial statements

UK GLOBAL HEALTHCARE LIMITED

Balance sheet statements

For the year ending 31 March 2024 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 19 May 2026
and signed on behalf of the board by:

Name: Ajay Gupta
Status: Director

The notes form part of these financial statements

UK GLOBAL HEALTHCARE LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2024

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

UK GLOBAL HEALTHCARE LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2024

2. Employees

2024 2023
Average number of employees during the period 2 2

UK GLOBAL HEALTHCARE LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2024

3. Fixed investments

Fixed asset investments are shown at cost less amounts written off. Provisions are made for permanent fluctuations in value.

UK GLOBAL HEALTHCARE LIMITED

Notes to the Financial Statements

for the Period Ended 31 March 2024

4. Off balance sheet arrangements

CONTINGENT LIABILITIES AND CONTINGENT ASSETS Legal Dispute with the UK Government. In May and June 2020, the company entered into two contracts for the supply of personal protective equipment (non-sterile nitrile examination gloves) during the Covid-19 pandemic giving a combined contract value of £30,700,000. The company received advance payments totalling £15,350,000 under these contracts which it used to secure the PPE from its onward supply chain. In October 2020, the UK Government purported to terminate both contracts and subsequently demanded repayment of the advance payments. The company disputes the validity of the termination on the grounds that goods were wrongfully rejected which complied with the contractual specification, and the UK Government failed to follow the contractual procedures for rejection and termination. The company's position, supported by legal advice, is that the purported termination was wrongful and that the company has a valid claim for breach of contract. The company has suffered losses including lost profits, lost deposits to suppliers, legal costs, management time, logistics and supply chain costs, laboratory testing costs, together with losses arising from the cancellation of supply chain contracts entered into in reliance on the contracts, including losses to its Indo UK Institute of Health Programme in India. In addition the company is in discussions with its supplier chain partners in South East Asia who have lost profits secondary to cancellation of their downstream contracts with company (due to rejection of PPE and termination of upstream parent contracts by UK Government with company) to circumvent any further liability towards them. The company has been engaged in ongoing correspondence and negotiations since 2020, including a mediation in July 2021 which resulted in Heads of Terms that were not subsequently implemented. Formal legal proceedings are in preparation. No provision has been made for repayment of the advance payments as the directors believe, based on legal advice, that the company has valid defences to the demand and that the purported termination was wrongful. The contingent asset in respect of the company's claim has not been recognised in these accounts as the outcome remains uncertain. The claim will be pursued through litigation if a negotiated settlement cannot be reached. The outcome of this dispute is inherently uncertain and could have a material impact on the company's financial position. Going Concern. The directors have considered the impact of the ongoing dispute on the company's ability to continue as a going concern. While the outcome of this dispute is uncertain, the directors believe it is appropriate to prepare these accounts on a going concern basis. This conclusion takes into account the company's current financial position, the strength of its legal claim, and the range of possible outcomes from the dispute.